MDM2 and Wilson disease: Given that senescence is a more desirable outcome of cytostatic therapy, we set out to define the mechanism controlling MDM2 turnover in response to PD0332991 in cell lines and then asked if this associates with the clinical outcome of WD/DDLS patients who were treated with palbociclib on a clinical trial.